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Abstract
Background: In most models of experimental thrombosis, healthy blood vessels are damaged. This results in the formation
of a platelet thrombus that is stabilized by ADP signaling via P2Y12 receptors. However, such models do not predict
involvement of P2Y12 in the clinically relevant situation of thrombosis upon rupture of atherosclerotic plaques. We
investigated the role of P2Y12 in thrombus formation on (collagen-containing) atherosclerotic plaques in vitro and in vivo,b y
using a novel mouse model of atherothrombosis.
Methodology: Plaques in the carotid arteries from Apoe
2/2 mice were acutely ruptured by ultrasound treatment, and the
thrombotic process was monitored via intravital fluorescence microscopy. Thrombus formation in vitro was assessed in
mouse and human blood perfused over collagen or plaque material under variable conditions of shear rate and coagulation.
Effects of two reversible P2Y12 blockers, ticagrelor (AZD6140) and cangrelor (AR-C69931MX), were investigated.
Principal Findings: Acute plaque rupture by ultrasound treatment provoked rapid formation of non-occlusive thrombi,
which were smaller in size and unstable in the presence of P2Y12 blockers. In vitro, when mouse or human blood was
perfused over collagen or atherosclerotic plaque material, blockage or deficiency of P2Y12 reduced the thrombi and
increased embolization events. These P2Y12 effects were present at shear rates .500 s
21, and they persisted in the
presence of coagulation. P2Y12-dependent thrombus stabilization was accompanied by increased fibrin(ogen) binding.
Conclusions/Significance: Platelet P2Y12 receptors play a crucial role in the stabilization of thrombi formed on
atherosclerotic plaques. This P2Y12 function is restricted to high shear flow conditions, and is preserved in the presence of
coagulation.
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Introduction
Rupture of an atherosclerotic plaque and occlusive arterial
thrombus formation is the major cause of acute cardiovascular
incidents and deaths in the Western countries [1]. The
development of a thrombus is a complex and dynamic process,
involving platelet aggregation, generation of thrombin and
formation of a network of fibrin, to strengthen the platelet
aggregate and stabilize the thrombus [2,3]. In vivo mouse models of
experimental thrombosis have indicated a major role of platelet
receptors in the process of thrombus formation and stabilization
[4]. However, the studies have been carried out by damaging
healthy mouse arteries in an artificial way, e.g. by laser-induced
tissue ablation, free radical-generating agents or mechanical
disruption. Thrombus formation in diseased, atherosclerotic
arteries following plaque rupture has hardly been investigated.
Ruptured atherosclerotic plaques expose several platelet-adhe-
sive and -activating components, such as collagen types I and III,
von Willebrand factor (VWF), lysophosphatidic acid, thrombos-
pondin, fibronectin, vitronectin, fibrin/fibrinogen and oxidized
low density lipoprotein [5,6,7,8,9,10]. In addition, plaques contain
tissue factor which, upon de-encryption, activates the extrinsic
coagulation system [5], while the intrinsic system of factor XII
activation is triggered via collagen [11]. To which extent each of
these plaque components contribute to thrombus formation is
unclear, though the platelet-activating roles of VWF and collagen
are well-described [1]. Collagen-bound VWF mediates the initial
tethering and transient adhesion of platelets via glycoprotein
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integrin aIIbb3 and adhesion to collagen via the platelet receptors,
GPVI and integrin a2b1 [2,12,13]. Recent in vitro studies suggest
that these receptors also mediate platelet adhesion to collagen in
damaged plaques [5,6]. Subsequent activation responses of
adhered platelets include mobilization of cytosolic Ca
2+, secretion
of autocoids like ADP, activation of integrin aIIbb3 (fibrinogen
receptor) and formation of pseudopods, all of which events help to
recruit circulating platelets into a thrombus [2,14]. Part of the
activated platelets become procoagulant by Ca
2+-dependent
exposure of phosphatidylserine on their surface, which is required
for local thrombin generation [15].
The autocrine agent ADP activates platelets via two receptors,
P2Y1 and P2Y12; the first of which mediates shape change and
initiates platelet aggregation, while the latter is required for
complete aggregation [16]. The importance of P2Y12 was revealed
by the observation that the damage of arteries in P2Y12-deficient
mice resulted in markedly delayed and unstable thrombus
formation [17]. Mechanistically, we and others have shown that
continuous signaling via P2Y12 is required to prevent platelet
disaggregation and to maintain aIIbb3 in its active conformation
[18,19]. The P2Y12 receptor also has a role in platelet
procoagulant activity by potentiating tissue factor-induced throm-
bin generation via sustained Ca
2+ mobilization [20,21].
In the present paper, we used a recently developed mouse
model of thrombus formation on acutely ruptured plaques to study
the role of P2Y12 receptors in atherothrombosis. We investigated
effects of the reversible P2Y12 antagonists, ticagrelor and
cangrelor, not only using this in vivo model, but also in perfusion
studies of whole (P2Y12-deficient) mouse or human blood perfused
over collagen-containing plaque material. The results point to a
P2Y12-dependent stabilization of thrombus formation at high
shear, that is maintained under conditions of coagulation. This
observation may have important implications for antithrombotic
treatment in patients.
Materials and Methods
Materials
Fibrillar Horm collagen (type I) was purchased from Nycomed
Pharma (Munich, Germany). Native fibrillar type I collagen was
prepared from bovine tendon with minimal protease treatment, as
described [22]. Fibrinogen labeled with Oregon Green (OG) 488
was from Invitrogen (Carlsbad, CA, USA). Carboxyfluorescein
diacetate succinimidyl ester (CFSE) was from Molecular Probes
(Leiden, the Netherlands). Rat-anti-mouse CD62 labeled with
FITC (Wug.E9) and rat-anti-mouse GPIIbIIIa (JON/A) labeled
with PE were from Emfret Analytics (Wu ¨rzburg, Germany).
Cangrelor (AR-C69931MX) and ticagrelor (AZD6140) were
kindly provided by AstraZeneca (Mo ¨lndahl, Sweden). Ketamine
and xylazine were from Eurovet (Bladel, the Netherlands). Sources
of other materials are described elsewhere [23].
Animals
Wild type C57BL/6 mice (12 weeks old) and Apoe
2/2 mice on
C57BL/6 background (4 weeks old) were obtained from Charles
River (Maastricht, The Netherlands). The Apoe
2/2 mice were fed
a Western-type diet with 0.15% cholesterol for 18–20 weeks, i.e.
until plaques had developed in the carotid arteries near the
bifurcation. Mice homozygously deficient in P2Y12 receptors [24]
and corresponding wild types (C57BL/6 background) were bred
and housed, as described previously [25]. Animal experiments
were approved by the research ethics committees of the
universities of Maastricht (The Netherlands) and Sheffield (UK).
In vivo plaque rupture and measurement of thrombus
formation
Acute rupture of plaques in the carotid arteries was provoked by
targeted ultrasound treatment, as described before [26]. Briefly,
Apoe
2/2 mice fed with cholesterol-containing diet were anesthe-
tized by subcutaneous injection of ketamine and xylazine (0.1 mg/
g and 0.02 mg/g body weight, respectively). The carotid arteries
were carefully dissected free from surrounding tissue, and the
anesthetized animals were injected intravenously with 10% CFSE-
labeled platelets, which were obtained from a donor mouse of the
same genotype. The mice were then injected with vehicle solution,
ticagrelor or cangrelor, as described below. Body temperature was
held at 37uC during all procedures.
Using brightfield illumination and intravital microscopy, a
plaque was selected in one of the carotid arteries near the
bifurcation. The tip (0.5 mm diameter) of a titanium ultrasound
probe was then placed at the plaque shoulder region. Rupture of
the plaque was induced by ultrasound application during 10 s at
6 kHz, using a VibraCell VCX130 processor (Sonics, Newtown,
CT, USA). Thrombus formation was recorded in real time by
capturing 12-bit fluorescence images at 33 Hz during at least
10 min, using a back-thinned electron multiplier C9100-12 EM-
CCD camera (Hamamatsu, Japan) at fixed gain settings. Local
rupture of the plaques was verified by two-photon laser scanning
microscopy and histological staining of sections of the carotid
arteries [26].
Time-series of fluorescence images were analyzed using Wasabi
(Hamamatsu) software. Per region of interest (ROI), correspond-
ing to the site of thrombus formation, total pixel intensity was
calculated and corrected for background intensity. To quantify
thrombus size, digital images taken at specific time points were
processed using ImagePro software (Media Cybernetics, Silver-
spring, MD, USA). Within the carotid artery, two similar ROIs
were defined, one representing the thrombus area and an adjacent
ROI representing the background. A threshold level was set by
eliminating all pixels with intensity lower than 99.0% of the pixels
of the background ROI. Intensities (gray levels) of all pixels in the
thrombus ROI were then integrated. No image processing was
applied.
In vivo administration of P2Y12 antagonist and blood
collection
Anesthetized mice were injected intravenously with vehicle
solution (5% mannitol in saline), ticagrelor (AZD6140) or
cangrelor (AR-C69931MX). Ticagrelor was infused at a dose of
420 mg/kg for 1 min, followed by 60 mg/kg/min for 15 min;
cangrelor was infused at 3 mg/kg/min for 15 min, and infusions
were continued during the experiment. Mice for control
experiments were bled retro-orbitally under anesthetics after
15 min of infusion of vehicle solution, ticagrelor or cangrelor.
Mouse blood was collected into 40 mM PPACK and 5 U/ml
heparin or trisodium citrate, as indicated [13]. Platelet-rich plasma
(PRP) was isolated and used for platelet activation analysis.
Human blood taken by venipuncture, was collected into 40 mM
PPACK or 12.9 mM trisodium citrate, as indicated.
Flow-cytometric evaluation of platelets with active aIIbb3 or P-
selectin exposure was performed by activation with ADP (40 mM)
or convulxin (100 ng/ml) in 20x diluted whole mouse blood,
followed by labeling with JON/A mAb or anti-CD62 mAb,
respectively. Detection of fluorescence was with a FACScan flow
cytometer, equipped with an argon laser (Becton-Dickinson,
Franklin Lakes, NJ). The percentage of positive cells was analyzed
using WinMDI 2.8 software (http://facs.scripps.edu).
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Human and mouse blood samples were perfused through a
parallel-plate transparent flow chamber containing a coverslip,
coated with either plaque material or collagen, as described [5].
PPACK-anticoagulated blood was used for perfusion experiments
without coagulation, respectively; ADP (10 mM) was co-perfused,
as indicated [18]. Coagulation was introduced by co-perfusion of
human or mouse citrate-anticoagulated blood with 0.1 volume of
CaCl2 (75 mM), MgCl2 (37.5 mM) and tissue factor (20 pM) in
Hepes buffer pH 7.45 (NaCl 110 mM, glucose 10 mM, Hepes
5 mM, KCl 2.7 mM and 0.1% bovine serum albumin). Wall shear
rate was 300–1000 s
21, as indicated. After blood perfusion,
thrombi on coverslips were rinsed with Hepes buffer supplemented
with 2 mM CaCl2, 2 mM MgCl2 and heparin (1 U/ml).
Recording of real-time videos and capturing of phase-contrast
images was with a non-confocal microscopic system [13]. Videos
were analyzed offline for embolizing events (single or clustered
platelets) per aggregate [18]. Randomly captured images were
analyzed for surface area coverage, area distribution of individual
segmented features or integrated fluorescence intensity with
Image-Pro (ImagePro, Silver Spring MD, USA) or Metamorph
software (MDS Analytical Technologies, Downingtown, PA, USA)
[27]. In specific experiments, OG488-fibrinogen (25 mg/ml) was
added to human or (P2Y12-deficient) mouse blood and, after
perfusion over collagen or plaque material, fluorescence accumu-
lation was detected by confocal laser scanning microscopy.
Confocal images were recorded off-line with a BioRad 2100
multiphoton system at fixed settings of argon laser power, scanning
rate and photomultiplier gain [15].
Coating of plaque material
Human atherosclerotic plaques were collected at autopsy from a
carotid artery and used in compliance with institutional guidelines
(Department of Pathology, Maastricht University). Permission was
obtained from the local Medical Ethics Committee. Murine
atherosclerotic plaques were collected from the aortic arches of 6
Apoe
2/2 mice, fed with a Western-type diet with 0.15% cholesterol
for 18–20 weeks. After resection, atherosclerotic specimens were
frozen into liquid nitrogen and stored at 280uC. Thawed human
and mouse atherosclerotic tissues were homogenized in phosphate-
buffered saline. Plaque homogenates were pooled at 165 mg wet
tissue weight/ml, as described [5]. Coverslips were coated with
plaque material at a density of 170 mg wet weight/cm
2.
Cone and plate(let) experiments
AnImpact-Rconeandplate(let)analyzer(CPA,DiaMed,Cressier,
Switzerland) was used to evaluate platelet adhesion and aggregation
on a surface under defined flow conditions [28]. Citrate-anticoagu-
lated blood (130 ml) was placed in a polystyrene well and subjected to
a shear of 500–5000 s
21 for 2 min. The platelet aggregates were
washed and stained by May-Gru ¨nwald stain, according to the
manufacturer’s instructions (DiaMed). Platelet deposition was
evaluated by an image analyzer system connected to the microscope,
measuring the average size of the aggregates in mm
2.
Thrombin generation experiments
Thrombin generation was measured in citrate-anticoagulated
human or mouse PRP (1610
8 platelets/ml), as before [29]. Briefly,
PRP was preincubated with inhibitors, and then treated with ADP
(20 mM) or vehicle for 10 min. Samples (4 volumes) were pipetted
into a polystyrene 96-wells plate (Immulon 2HB, Dynex Technol-
ogies, Chantilly, VA,USA), alreadycontaining1 volume ofbufferA
(20 mM Hepes, 140 mM NaCl and 0.5% bovine serum albumin)
and tissue factor (6 pM). Coagulation was started by adding 1
volume of buffer B (2.5 mM Z-GGR-AMC, 20 mM Hepes,
140 mM NaCl, 100 mM CaCl2 and 6% bovine serum albumin).
Samples were run at least in duplicate. First-derivative curves of
accumulation of fluorescence in human plasma were converted into
nM thrombin using a human calibrator.
Statistical analysis
Data are presented as means 6 SE. Groups were compared
using the non-parametric Mann-Whitney U test (one-tailed) using
the statistical package for social sciences (SPSS 15.0, Chicago, IL,
USA). Size distribution of platelet aggregates was evaluated by x
2
analysis [27]. A p-value below 0.05 was considered significant.
Results
Inhibition of mouse P2Y12 receptors causes unstable
thrombus formation after rupture of an atherosclerotic
plaque
To study the role of platelet P2Y12 in atherothrombosis, we used
a recently established mouse model of acute plaque rupture [26].
Mice deficient in ApoE were fed a cholesterol-enriched diet for
18–20 weeks. Plaque-containing carotid arteries were dissected
free from surrounding tissue, and CFSE-labeled Apoe
2/2 platelets
were injected to enable measurement of fluorescence by intravital
microscopy. In control animals infused with vehicle solution,
targeted treatment with an ultrasound probe resulted in acute
rupture and subsequent non-occlusive thrombus formation
(Fig. 1A). As described, this thrombotic process relies on GPVI-
induced platelet activation as well as on thrombin generation and
coagulation [26]. Mice were infused with effective concentrations
of one of the reversible P2Y12 antagonists, ticagrelor or cangrelor.
In blood samples taken from some of these mice, it was checked
that the ticagrelor or cangrelor interventions abolished ADP- and
collagen-induced platelet aggregation (data not shown). In other
mice, the infusion of either P2Y12 antagonist greatly suppressed
platelet accumulation induced by carotid plaque rupture, in that
only loose thrombi appeared, which consisted of single-layered
fluorescent platelets, in contrast to the compact bright fluorescent
thrombi in vehicle-treated mice (Fig. 1B). The reduced thrombus
formation was also apparent from time-courses of integrated
fluorescence intensity after plaque rupture (Fig. 1C). Similarly as
described [26], in vehicle-treated mice, plaque rupture caused a
biphasic pattern of rapid increase and slower decline in
fluorescence accumulation. Only few single platelets were seen
to leave the thrombus in the declining phase. Since fluorescence
bleaching was relatively low, the declining phase had a different
cause, likely contraction of the platelet-fibrin thrombus.
Off-line quantification of images showed that P2Y12 inhibition
with either antagonist reduced the size of thrombi compared to the
vehicle control (Fig. 1D). Video analysis further revealed that the
thrombi formed in the presence of P2Y12 inhibitor were relatively
unstable. With ticagrelor or cangrelor present, 4–5 fold more
emboli were shed from thrombi in comparison to control mice
(Fig. 1E). Together, these data pointed to a marked inhibiting
effect of the reversible P2Y12 antagonists on in vivo thrombus
formation following plaque rupture.
Absence of functional P2Y12 receptors suppresses
thrombus formation and thrombin generation, but
increases disaggregation
To study the mechanism by which P2Y12 contributes to
thrombus stabilization, we performed flow chamber experiments
P2Y12 in Atherothrombosis
PLoS ONE | www.plosone.org 3 April 2010 | Volume 5 | Issue 4 | e10130Figure 1. Inhibition of P2Y12 receptors causes unstable thrombus formation on acutely ruptured plaques in mice. Apoe
2/2 mice were
infused with vehicle solution as a control. Other mice were infused with ticagrelor (210 mg/kg for 1 min, followed by 30 mg/kg/min during the
experiment). In the third group of mice, cangrelor was continuously infused at 3 mg/kg/min. Infusion of ticagrelor and cangrelor started at 15 min
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2/2 mice which
were infused with ticagrelor. Perfusion of blood from ticagrelor-
treated mice resulted in diminished thrombus formation on
collagen (Fig. 2A). The treatment significantly reduced platelet
deposition, while it increased the disaggregation events (Fig. 2B,
C). Flow cytometry using whole blood from mice infused with
ticagrelor demonstrated near complete inhibition of aIIbb3
activation in response to ADP and of P-selectin expression in
response to low convulxin (Fig. 2D).
To confirm the role of P2Y12 in these platelet responses,
experiments were performed with blood from P2Y12-deficient
mice. Perfusion of blood from these mice also resulted in
diminished thrombus formation (Fig. 3A), accompanied by
increased disaggregation events (Fig. 3B). Furthermore, flow
cytometry using whole blood from P2Y12-deficient mice demon-
strated complete inhibition of aIIbb3 activation in response to ADP
and of P-selectin expression in response to low convulxin (Fig. 3C).
Ticagrelor was without further effect on these responses of P2Y12-
deficient platelets (not shown).
Since enhancement of platelet-dependent thrombin generation
is an established outcome of P2Y12 signaling [20], effects of P2Y12
antagonism on thrombin generation were investigated in mouse
and human PRP. Dose-response experiments demonstrated that
20 mM ticagrelor or cangrelor were maximally effective (data not
shown). At this concentration, either antagonist partly reduced the
stimulating effect of ADP on thrombin peak levels in mouse and
human PRP (Fig. 4A, C). Since in particular the rate of thrombin
generation is an important parameter in flow-dependent thrombus
formation, we quantified the slope of the thrombin generation
curves for effects of P2Y12 inhibition. both ticagrelor and cangrelor
markedly suppressed this slope in mouse and human PRP (Fig. 4B,
D). We reasoned that this contribution of P2Y12 may play a role in
thrombus stabilization by increasing the availability of thrombin to
activate platelets and form fibrin fibers.
Inhibition of P2Y12 impairs thrombus formation and
stabilization at high but not low shear rate
The clinical efficacy of P2Y12 antagonists may depend on the
local shear rate, which can vary considerably at arterial sites of
vulnerable atherosclerotic plaques. To investigate this, human
blood was perfused at low and high shear rate over a collagen-
containing surface under physiological conditions allowing
coagulation. Under control conditions in the absence of
P2Y12 inhibitors, stable thrombi containing platelets and fibrin
were formed at shear rates of 300 to 1000 s
21 (Fig. 5A). Fibrin
fibers were most clearly visible between adjacent thrombi. In
the presence of ticagrelor or cangrelor, much smaller thrombi
were formed. Especially at 1000 s
21, fibrin fiber formation and
the average thrombus size were drastically reduced with
ticagrelor (Fig. 5B). Analysis of the size distribution patterns
on coverslip showed that ticagrelor suppressed the formation of
larger thrombi (.400 platelets) only at this higher shear rate
(Fig. 5C). Interestingly, this was accompanied by a twofold
increase in disaggregation events, again only at 1000 s
21
( F i g .5 D ) .S i m i l a re f f e c t so fP 2 Y 12 inhibition on thrombus
stabilization at high shear were seen in flow studies without
coagulation (not shown). Together, these experiments indicated
that, under conditions of high shear and coagulation, P2Y12
antagonism suppressed the formation of stable, fibrin-contain-
ing thrombi.
To confirm the shear-dependent effect of P2Y12 inhibition,
additional whole blood experiments were performed with a cone
and plate(let) analyzer. This test evaluates platelet adhesion and
aggregation to a surface under defined shear conditions [28]. At a
low shear rate of 500 s
21, the size of the platelet aggregates was
not influenced by ticagrelor or cangrelor (Fig. 6A, B). However, at
5000 s
21, the larger size aggregates became greatly sensitive to
P2Y12 inhibition. This experiment hence supports the conclusion
that P2Y12 contributes to thrombus formation especially at high
shear rate.
Inhibition or deficiency of P2Y12 suppresses thrombus
formation on plaques under high shear flow
To approach the clinical situation, plaque tissue was isolated
from large atherosclerotic vessels obtained by autopsy. Cell-free
homogenates were prepared from pools of four plaques [5], and
these were used as thrombogenic surface for flow chamber
studies. Human blood, supplemented with OG488-labeled
fibrinogen, was perfused over the plaque homogenate, again
under conditions of high shear and coagulation. This resulted in
the assembly of large, fluorescent thrombi, which were
interconnected by fluorescent fibrin fibers (Fig. 7A). Preincuba-
tion of the blood with ticagrelor or cangrelor substantially
r e d u c e dt h r o m b u ss i z ea sw e l la sf i b r i nf i b e rf o r m a t i o n( F i g .7 B ,
C). That thrombus size was reduced with either P2Y12
antagonist was further confirmed by morphometric analysis of
the platelet aggregates (Fig. 7D). This was in agreement with
analysis of the disaggregation events during blood flow, pointing
to a marked destabilization of the thrombi formed in the
presence of ticagrelor or cangrelor (Fig. 7E).
To confirm these results based on pharmacological inhibition
of P2Y12, flow experiments were performed using blood from
P2Y12-deficient mice. Blood was perfused over homogenized
plaque material, which was isolated from atherosclerotic aortic
arches of cholesterol-fed Apoe
2/2 mice. Perfusion of P2Y12-
deficient blood over this material resulted in greatly reduced
thrombus formation,leaving onlya monolayerof plateletsat the
plaque surface (Fig. 8A). Deficiency in P2Y12 also suppressed
the deposition of OG488-fibrinogen. Image analysis pointed to
a significant reduction in both overall thrombus size (Fig. 8B)
and label accumulation (Fig. 8C). Morphometric analysis
showed the formation of more smaller aggregates with P2Y12-
deficient blood (Fig. 8D). These thrombi were instable, as
appeared from analysis of the platelet disaggregation events
during flow (Fig. 8E).
Altogether these results indicate that ADP, via P2Y12, stabilizes
thrombi formed under flow on ruptured plaques in the mouse
carotid artery in vivo, and on human and mouse plaque material in
before ultrasound treatment. (A) Brightfield image of a carotid plaque (p) with ultrasound probe (up). Further, raw fluorescence images (left) and
threshold masked images (right) of CFSE-labeled platelets before and after ultrasound treatment. Dotted area indicates location of carotid artery
(bars, 100 mm). Time stamps point to images at baseline (210 s) or after plaque rupture (20 s). (B) Representative threshold masked images of
thrombi on ruptured plaques of mice infused with vehicle, ticagrelor or cangrelor (bar, 100 mm). Note the microthrombi with P2Y12 antagonist
formed within 1 min of ultrasound treatment. (C) Time-courses of integrated CFSE fluorescence intensity above background (arbitrary units, AU) of
representative thrombi formed. (D) Quantification of thrombus size at various time points after ultrasound treatment. Data are integrated
fluorescence intensities from threshold masked images. (E) Number of fluorescent emboli shed during 3 min after plaque rupture. Data are means 6
SE (n=3–8), *p,0.05 and
#p,0.1 compared to vehicle.
doi:10.1371/journal.pone.0010130.g001
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Apoe
2/2 mice were infused with vehicle solution, ticagrelor or cangrelor (see Figure 1). (A–C) PPACK/heparin anticoagulated blood from treated mice
was perfused over native type I collagen at a shear rate of 1000 s
21 for 4 min. (A) Representative phase-contrast images after 4 min perfusion
(bar=20 mm). (B) Quantitative effect of ticagrelor on surface area coverage by platelets. (C) Average number of disaggregation events measured from
a preformed aggregate during flow. (D) Flow-cytometric evaluation in whole blood of platelets with active aIIbb3 (JON/A mAb) by activation with ADP
(20 mM), and of platelets exposing P-selectin (anti-CD62 mAb) by activation with convulxin (Cvx, 10 ng/ml). Bars give percentages of positive
platelets. Data are means 6 SE (n=3–4), *p,0.05.
doi:10.1371/journal.pone.0010130.g002
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thrombus stability increases with shear rate and is maintained in
the presence of coagulation.
Discussion
In the present paper, we used a novel in vivo mouse model of
thrombus formation on acutely ruptured atherosclerotic
plaques, to demonstrate a marked antithrombotic effect of
two reversible blocking agents of the platelet P2Y12 receptors,
i.e. ticagrelor and cangrelor. Both P2Y12 inhibitors destabilized
thrombus formation by increasing the embolization of
platelets, with as a result smaller sized thrombi. Our data
extend earlier findings, using the same model of acute
atherothrombosis, which indicated that thrombus formation
is the result of a multi-factorial process involving: platelet
interaction with collagen, exposure of tissue factor, generation
of thrombin, and formation of fibrin fibers [26]. Recently,
other authors have confirmed the importance of collagen and
thrombin, using the same model of carotid plaque rupture by
ultrasound [30]. Since these in vivo data pointed to collagen as
a major thrombogenic component in the carotid plaque, we
continued to study thrombus formation by in vitro perfusion
studies with immobilized plaque material or native collagen as
a surface. However, it should be noted that also other
thrombogenic components have been identified in plaque
Figure 3. Deficiency in mouse P2Y12 receptors diminishes thrombus formation on collagen and provokes disaggregation under
flow. Blood from P2Y12 deficient (P2Y12
2/2) or wild type (P2Y12
+/+) mice was perfused over native type I collagen at 1000 s
21 for 4 min in the
presence of 10 mM ADP. (A) Quantitative effect of P2Y12 deficiency on surface area coverage by platelets. (B) Average number of disaggregation
events measured from a preformed aggregate during flow (n=3). (C) Flow-cytometric evaluation of ADP-stimulated platelets with active aIIbb3 (JON/
A mAb) and of convulxin-stimulated platelets exposing P-selectin (anti-CD62 mAb) in whole blood. Experiments were performed as in Fig. 2. Data are
means 6 SE (n=5–6), *p,0.05.
doi:10.1371/journal.pone.0010130.g003
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teins and lysophosphatidate [8,10,31].
A key role of platelet P2Y12 receptors in thrombus stabilization
was confirmed by in vitro flow studies using either mouse or
human blood. Markedly, when coagulation was introduced,
blockage or deficiency of P2Y12 suppressed the formation of
larger sized platelet aggregates as well as the formation of fibrin
fibers, in particular at high shear rate. Furthermore, inhibition or
absence of P2Y12 destabilized the thrombi formed on immobi-
lized collagens or plaque material. Also cone-and-plate(let)
experiments, where platelets adhered to a surface, showed an
enhancing effect of P2Y12 on thrombus formation at high but not
low shear rate.
In earlier work, we and others have shown that autocrine,
platelet-derived ADP contributes to thrombus growth and stability
on collagen-containing surfaces [18,32,33]. The present data
confirm this and indicate that, in addition, the thrombus-
stabilizing role of P2Y12 is maintained in the presence of
coagulation. Mechanistically, P2Y12 can contribute to the
formation of stable thrombi via two different processes: (i)
continuous signaling to phosphoinositide 3-kinases b and c with
as a result sustained aIIbb3 activation [18]; (ii) enhancement of
thrombin/fibrin generation due to increased Gi-mediated Ca
2+
mobilization and platelet procoagulant activity [20,21,34]. The
observations that ticagrelor and cangrelor retards ADP-dependent
thrombin generation and fibrin formation relates to the latter
function. In conjunction with the present results, others have
reported that P2Y12 is implicated in shear-induced platelet
aggregation via activation of Syk kinase and phosphoinositide 3-
kinase [35]. Interestingly, another study describes no effect of
cangrelor of collagen-dependent thrombus formation [36].
However, this study focused short-term processes (,1.5 min),
during which thrombi are still in the growing phase and the
contribution of adhesive receptors such as GP-Ib-V-IX is relatively
high. Our time-dependent analysis however indicates that a role of
P2Y12 becomes more prominent at later stages.
The P2Y12-directed prodrug clopidogrel is increasingly used to
prevent secondary ischemic events in patients with myocardial
infarction or stroke [37,38]. Recently, clinical studies performed
with the new, irreversible P2Y12 inhibitor prasugrel [39,40] and
Figure 4. Procoagulant role of P2Y12 receptors in platelet-dependent thrombin generation. Mouse (A, B) or human (C, D) PRP was
preincubated with vehicle, ticagrelor (20 mM) or cangrelor (20 mM), and stimulated with ADP (20 mM). Thrombin generation was measured after
triggering with tissue factor (1 pM) and CaCl2 (16.7 mM). (A, C) Representative thrombin generation curves of PRP stimulated with ADP alone, or ADP
in combination with P2Y12 inhibitor. (B, D) Quantitative effect of ticagrelor or cangrelor on ADP-stimulated rate of thrombin formation. Data are
means 6 SE (n=3–6), *p,0.05 compared to ADP + vehicle.
doi:10.1371/journal.pone.0010130.g004
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promising results for the treatment of acute coronary syndrome.
Our findings suggest that the success of such anti-P2Y12
interventions relies on the selective abrogation of a platelet
response–autocrine activation of P2Y12–that is at least in part
dependent on the local, high shear conditions.
In summary, we have shown that ADP, via P2Y12,s t a b i l i z e s
thrombi on ruptured plaques both in vivo and on human
Figure 5. Inhibition of P2Y12 receptors affects collagen-dependent thrombus formation at high but not low shear rate. Citrate-
anticoagulated human blood, recalcified with CaCl2/MgCl2 in the presence of 2 pM tissue factor, was perfused over Horm type I collagen at a shear
rate of 300 or 1000 s
21. Blood samples were preincubated with vehicle, ticagrelor (20 mM) or cangrelor (10 mM), as indicated. (A) Representative
phase-contrast images after 4 min of perfusion (bar=20 mm). (B) Average size of thrombi formed in treated blood samples at different shear rates. (C)
Frequency distribution of feature size on coverslips; estimated numbers of platelets per feature (aggregate) were: 9–24 (white), 24–75 (light gray), 75–
400 (dark gray) and .400 (black). (D) Number of disaggregation events from individual aggregates in the 4th minute of blood perfusion at 300
or1000 s
21. Data are means 6 SE (n=3–9), *p,0.05 compared to vehicle.
doi:10.1371/journal.pone.0010130.g005
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pendency of thrombus stability is maintained in the presence
of coagulation, but most pronounced at high shear flow
conditions.
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Figure 6. Inhibition of P2Y12 receptors reduces aggregate size at high but not low shear in cone and plate(let) analyzer.
Citrate-anticoagulated human blood was preincubated with vehicle, ticagrelor (20 mM) or cangrelor (10 mM) for 10 min. Blood samples were
subjected to a shear rate of 500 or 5000 s
21 for 2 min in a cone and plate(let) analyzer (CPA). (A) Representative images of platelet
aggregates formed on the surface after 2 min (bar=20 mm). (B) Average aggregate size in mm
2. Data are means 6 SE (n=4–6), *p,0.05
compared to vehicle.
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from fibrin(ogen)-binding platelets and thrombi. (D) Histograms of features on surface; the estimated numbers of platelets per feature were 9–24
(white), 24–75 (light gray), 75–400 (dark gray) and .400 (black). (E) Disaggregation events measured per platelet aggregate per min. Data are means 6
SE (n=3), *p,0.05,
#p=0.06 compared to vehicle.
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